Literature DB >> 7670748

Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior.

D L Tribble1.   

Abstract

Atherosclerosis susceptibility associated with elevations in specific populations of apolipoprotein-B-containing particles may involve increased oxidation of lipoproteins and associated changes in their biological properties. Lipoprotein oxidation may be potentiated by the greater mass of oxidizable lipoprotein substrates, as well as by a greater intrinsic susceptibility of the specific forms of lipoproteins that arise in these disorders. The atherogenic consequences of increased lipoprotein oxidation may be further enhanced by a greater relative potency or toxicity of the oxidized products of these lipoprotein subpopulations. This review addresses these facets of lipoprotein oxidation in several forms of dyslipidemia, and in view of both differences between and commonalities among these disorders, proposes that lipoprotein oxidative behavior is determined by a complex array of physical, chemical, and metabolic factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670748

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  7 in total

Review 1.  LDL particle size: an important drug target?

Authors:  I Rajman; P I Eacho; P J Chowienczyk; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

Review 3.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.

Authors:  M Vázquez; D Zambón; Y Hernández; T Adzet; M Merlos; E Ros; J C Laguna
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

5.  Protective effect of oleuropein, an olive oil biophenol, on low density lipoprotein oxidizability in rabbits.

Authors:  E Coni; R Di Benedetto; M Di Pasquale; R Masella; D Modesti; R Mattei; E A Carlini
Journal:  Lipids       Date:  2000-01       Impact factor: 1.880

6.  Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins.

Authors:  Elena de Juan-Franco; Antonio Pérez; Vicent Ribas; Juan Antonio Sánchez-Hernández; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; José Luis Sánchez-Quesada
Journal:  Int J Biomed Sci       Date:  2009-12

7.  Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice.

Authors:  Andrea Rivas-Urbina; Anna Rull; Joile Aldana-Ramos; David Santos; Nuria Puig; Nuria Farre-Cabrerizo; Sonia Benitez; Antonio Perez; David de Gonzalo-Calvo; Joan Carles Escola-Gil; Josep Julve; Jordi Ordoñez-Llanos; Jose Luis Sanchez-Quesada
Journal:  Biomolecules       Date:  2020-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.